MedPath

Proteomics study in patients with severe malaria

Recruiting
Conditions
Severe malaria(P vivax and P falciparum)Non malarial feverHealthy participants
Registration Number
CTRI/2013/08/003876
Lead Sponsor
Department of Biosciences and Bioengineering Indian Institute of Technology
Brief Summary

Malaria is amajor health problem in Asia and Africa and to date more than 1 million peopledie annually due to this diseaseLack of early diagnosis effectivevaccines as well as drug resistance remains major challenges The incidence ofmalaria from *P* *vivax* and *P  falciparum* speciesof the malaria parasite and its complications is on the rise worldwide withreports of mortality from what was thought to be an otherwise benign parasite  Proteomic investigations of the *P vivax*and *P falciparum* along with the studyof host immune responses may significantly advance our understanding andperhaps aid prognosis

Thisproject aims to perform a comprehensive proteomic analysis of serum samples ofsevere *P falciparum* malaria and *P vivax* malaria patients admitted in Departmentof Clinical Pharmacology Seth GS Medical College and KEM Hospital We will perform thecomparative serum proteome analysis of and healthy controls severe andnon severe FM and VM malaria patients using 2DE and 2D DIGE in combination withMALDI TOF/TOF MS to decipher disease pathogenesis host immune response andidentification of surrogate protein markers  Proteomic andimmunoassay based analysis of the clinical samples will be performed at Departmentof Biosciences and Bioengineering Indian Institute of Technology Bombay Powai Mumbai 400 076 India Diagnostic impact of identified serum biomarkers inclinics and specificity for malaria prediction will be established byinvestigation of the disease patterns in large clinical cohorts usingimmunoassay-based analysis Panel of identified biomarkers will be tested toevaluate their efficiency in diagnosis. Expression levels of the identifiedserum protein in severe malaria patients will help to correlate the identifiedmarker proteins with disease severity and evaluate the prognostic value of thetarget proteins Specificity of the identified malaria related serum markers willbe evaluated by means of analysis of dengue fever and leptospirosis as febrilecontrols

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
300
Inclusion Criteria

Participants of either sex aged 18 to 65 years both inclusive Either gender with a diagnosis of severe/complicated vivax malaria OR with a diagnosis of severe malaria due to mixed infection Confirmed nonmalaria fever patients dengue fever (serum IgM antibody titre) leptospirosis (microscopic agglutination test)and enteric fever (widal test) Healthy volunteers as judged by medical history clinical examination and laboratory investigations Patients or their legally accepted representatives willing to provide written informed consent.

Exclusion Criteria

Patients with history of significant systematic disease like autoimmune disorders chronic liver diseases psychiatric illness and bleeding disorders etc As judged by history and physical examination Patients with a diagnosis of complications to dengue leptospirosis or any other infectious disease A female patient who is pregnant at enrolling.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum proteome analysis of patients suffering from severe P vivax and P falciparum malaria infections to get mechnistic insights about disease pathogenesis and host immune responsesingle time
Identification of potential serum markers associated with severe versus uncomplicated malariasingle time
Correlation of the identified serum markers with disease severity establishment of prognostic host markers of malariasingle time
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Clinical Pharmacology

🇮🇳

(Suburban), MAHARASHTRA, India

Department of Clinical Pharmacology
🇮🇳(Suburban), MAHARASHTRA, India
Dr Nithya Gogtay
Principal investigator
2224174420
njgogtay@hotmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.